Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 28, 2024
Reporting Period: This filing reports a specific event on March 28, 2024, rather than a financial period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a disclosure of a corporate presentation update and does not contain financial statements or quantitative performance data.
Material Changes
Item 7.01 Regulation FD Disclosure: The Company updated its corporate presentation intended for use at various conferences and investor meetings. This updated presentation is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the update of the corporate presentation but does not include specific text regarding guidance, outlook, or management commentary within the body of the 8-K.
Legal Disclaimer: The information contained in Item 7.01 and the attached Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that Section, nor is it incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Corporate Presentation dated March 28, 2024) for specific details on the company's strategy, pipeline, and financial outlook, as the 8-K body only references this document.
- Verify the trading symbol MTNB on the NYSE American exchange.
- Confirm that the updated presentation has not been incorporated by reference into other regulatory filings unless explicitly stated.